BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
26 hedge funds and large institutions have $4.65M invested in BRAINSTORM CELL THERAPUTC in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 3 closing their positions.
4,088% more call options, than puts
Call options by funds: $335K | Put options by funds: $8K
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
18% more capital invested
Capital invested by funds: $3.94M → $4.65M (+$710K)
0.16% less ownership
Funds ownership: 0.55% → 0.39% (-0.16%)
4% less funds holding
Funds holding: 27 → 26 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$267K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$60.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.9K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$36.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.02M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$629K |
| 3 |
SEI Investments
Oaks,
Pennsylvania
|
-$16K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$3K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$2.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
PA
27
Perceptive Advisors
New York
| – | -$1.02M | -26,667 | Closed |
|
|
28
SEI Investments
Oaks,
Pennsylvania
| – | -$16K | -420 | Closed |
|
|
29
Creative Planning
Overland Park,
Kansas
| – | -$3K | -67 | Closed |
|
BCLI Hedge Fund Activity: Q1 2017 in Review
26 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2017, worth a combined $4.65M — up 18% from $3.94M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCLI positions and 3 closed out — a net gain of 3 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $267K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.02M sold.
- 26 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2017, down from 27 in Q4 2016.
- Funds reported $4.65M of BRAINSTORM CELL THERAPUTC stock for Q1 2017, up 18% quarter-over-quarter.
- 6 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2017 and 3 closed out, a net change of +3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2017 was BlackRock, an estimated $267K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2017 was Perceptive Advisors, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2017.